John Poyhonen, Director at HERON THERAPEUTICS, INC. /DE/ (HRTX), bought 3,000 shares at $17.55 ($53K) on 2019-05-22, disclosed to the SEC on 2019-05-23.
Open-market purchase of $53k HRTX by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.
| Filing → |
| HRTX | BUY | 2017-01-23 | $122K | — | Filing → |
| SNMX | SELL | 2014-06-06 | $301K | — | Filing → |
| RDEA | SELL | 2011-06-03 | $136K | — | Filing → |